Member Info for EmeraldCarrots

Up 1.2%

so one would think CCL will have a very good day...........

Up 13.41%. Nice.

Current sp to have any chance of succeeding IMHO. As you point out with further funding there is no reason why the Parsortix technology could not get FDA clearance for medical use with cancers other than breast thus increasing the available market by something like 90%. I hasten to add the existing Breast cancer market combilned with the enourmous cancer drug trials markets should be easily enough for Angle Plc as it stands. To get a bid Angle need a decent sized pharma Co. to realise the potential here.

All IMHO.

Gawdhelpus !

MM's back on the ball. Bid 19p/ask 20p. Don't see them offering the same price for both very often........ LOL!

Something big happening????

Trials by using Angle's Parsortix machine to catch the circulating tumour cells for testing. Potentially there may also be a massive market for testing the patients circulating tumour cells to see if they are suitable for the Immunotherapy treatment in the first place.

https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

All IMHO.

Up 4%.

TwoGood2Die. Clearly you did not look at the presentation (see link below). You really need to stop posting complete and utter rubbish on this bb and actually look at the presentations. Then you might post something that is actually true and is based on fact not complete fiction>>:-

The research side enables the monitoring of both HER2 and PD-L1 proteins using the Parsortix system to catch circulating tumour cells to test. You comments inferring they don't have enough potential clients are utterly ridiculous. HER2 and PL-L1 are proteins that can be targeted by modern Immunotherapy drugs. As you know unlike some other systems these cancer cells Parsortix catches are 99% alive and intact, ideal for analysing/testing. These Companies like AstraZeneca desperately need more feedback from their Immunotherapy drug trials involving HER2 and PD-L1. Although in some cases the drugs work extremely well sometimes, they don't and there is no *****conclusive proof***** as to why. For HER2 it is suspected the cancers status sometimes changes from HER2 positive to negative thus evading the targeted treatment. Same story with PD-L1. Using Parsortix these drug trial Companies could have the ability to monitor the HER2 and PD-L1 status of these proteins before, during and after a drug treatment. This could give invaluable information going forward to the Companies doing the trials. Look at the presentation (see link below) 13 mins 20 sec in. Mr Newland explains this top 100 Japanese Company (Eisal Inc.) with revenues over $4 BILLION and 80 active oncology trials involving more than 60,000 participants have contracted Angle to do a pilot study. I suggest they are on the ball and the first of many Companies that will use Parsortix to further their knowledge about the drug that have developed. In time Parsortix could be used at cancer clinics to find out which patients are most suitable for these treatments and which ones are not. Huge potential.

https://www.youtube.com/watch?v=cnQ6M05BiBY

https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/

Reply

Up 4%.

large trade to appear later.

Probably!

Proteins using the Parsortix system to catch circulating tumour cells to test. You comments inferring they don't have enough potential clients are utterly ridiculous. HER2 and PL-L1 are proteins that can be targeted by modern Immunotherapy drugs. As you know unlike some other systems these cancer cells Parsortix catches are 99% alive and intact, ideal for analysing/testing. These Companies like AstraZeneca desperately need more feedback from their Immunotherapy drug trials involving HER2 and PD-L1. Although in some cases the drugs work extremely well sometimes, they don't and there is no *****conclusive proof***** as to why. For HER2 it is suspected the cancers status sometimes changes from HER2 positive to negative thus evading the targeted treatment. Same story with PD-L1. Using Parsortix these drug trial Companies could have the ability to monitor the HER2 and PD-L1 status of these proteins before, during and after a drug treatment. This could give invaluable information going forward to the Companies doing the trials. Look at the presentation (see link below) 13 mins 20 sec in. Mr Newland explains this top 100 Japanese Company (Eisal Inc.) with revenues over $4 BILLION and 80 active oncology trials involving more than 60,000 participants have contracted Angle to do a pilot study. I suggest they are on the ball and the first of many Companies that will use Parsortix to further their knowledge about the drug that have developed. In time Parsortix could be used at cancer clinics to find out which patients are most suitable for these treatments and which ones are not. Huge potential.

https://www.youtube.com/watch?v=cnQ6M05BiBY

https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/

To me this discussion is fairly unimportant. Angle have FDA approval for hospitals using the Parsortix machine to catch circulating tumour cells (CTC's) from a blood sample from someone with metastasized breast cancer to get the HER2 status of the cancer etc.......... That market World wide is more than enough on it's own. I'm far more interested in the last announcement which basically says the partnership with Bioview to develop an automated CTC HER2 assay which uses A.I. is coming along nicely. PD-L1 to follow looks logical does it not............................................................?

https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html

So it's only down 0.56% in the last 5 days, as you have posted.

Not as bad as it might look today then.

Similar the the HER2 one but targeting PD-L1 evaluation........................

That would cover most of the Immunotherapy drugs available that are all over the news.

And the sp is down!

Davey50.

Whoever sold the 450,000 will regret it I think.

The Bioview / Angle partnership to market a system that will enable medics to find out the HER2 status of a persons cancer from a simple standard blood test CANNOT BE IGNORED! This information is key to selecting the patients that the Immunotherapy drug targeting HER2 positive patients will work on! Massive savings finding out which ones it will NOT work on of course....... Just a matter of time before we get the RNS to confirm the product launch, or to confirm the other pharma partner they may do a deal with.......... Massive potential for AGL............... MASSIVE!

All IMHO.

Bar none once launched as far as I am aware. It took 6 years for AGL to get their FDA authorisation............

Two very recent examples involving Astrazeneca where HER2 status is key:-

https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

All IMHOl

Highly likely to be a massive winner once launched. We had an update Monday:

https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html

Don't forget Bioview invested £1.2 million of their own cash to develop this which would leverage BOTH Companies FDA accreditation which means the machines are allowed to be used in the USA. The ONLY one ????????????

Immunotherapy targeting a cancers HER2 status is all over the news of late.

Two very recent examples involving Astrazeneca:-

https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

All IMHO.

Highly likely to be a massive winner once launched. We had an update just last Monday:

https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html

Don't forget Bioview invested £1.2 million of their own cash to develop this which would leverage BOTH Companies FDA accreditation which maens the machines are allowed to be used in the USA................

All IMHO.

Nice!

Bantham.

So that says - full approval in the US for Breast cancer. No restrictions. Good.

And it says use for all other cancers restricted to drug trials.

Is that correct?

----------------------------------------------------

I believe that is correct. Just the Breast cancer side alone could swamp Angle Plc.

Basically the potential size of the market is quite incredible.

miavoce and TwoGood2Die were arguing over additional potential market from other services labs.

miavoce posted this:-

"Wrong TGTD. CLIA labs do not need FDA approval to use parsortix for testing any cancer types. As long as the labs have validated the tests that they are offering then there is nothing stopping them from offering the test. This is why Angle are developing the Ovarian and Prostate tests (clearly there would be no point them doing this if lack of FDA approval would prevent the tests being carried out by labs).".

I think other Pharma Services Co's who have the CLIA accreditation can offer tests on circulating tumour cells that ***happened to have been obtained*** using the Parsortix machine ***"as long as the labs have validated the tests that they are offering"*** as miavoce said. So I believe there is additional market here too.

All IMHO.

Therefore is can be used anywhere in the USA to catch Circulating Tumour Cells (CTC's) from people who have metastasized Breast Cancer. Also as American FDA approval is the "gold standard" most other countries will approve it's use too. These CTC's can then be tested to find out for example the cancers current HER2 status, before (if necessary) , during and after treatment. As we know a cancers HER2 status can change over time. The point here is that some modern drugs can target cancers that are HER2 positive (they lock on and deliver poison to the cell). So a tissue biopsy from the original surgically removed lump might be HER2 positive. Then the person may well be given a treatment that targets HER2 cancer cells. All well and good. If however the cancer changes to HER2 negative during treatment then the drug that targets HER2 won't lock on and so the drug won't work. If the change to HER2 negative is known then the treatment can of course be changed. The breast cancer market alone is enormous.

Then there is the massive World wide drug trials market. Parsortix can be used in this scenario for any cancer, not just Breast. In the following video it says Eisai Inc. (top 100 Co. in Japan) have 80 active cancer trials with 60,000 participants. That is just one Japanese Company.............. See 14 mins 45 secs in to this video:-

https://www.youtube.com/watch?v=cnQ6M05BiBY

https://www.youtube.com/watch?v=ZqaWMUx7GhE

All IMHO.